HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.

Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death in Japan. Pancreatic cancer is categorized as resectable, borderline resectable, or unresectable based on the degree of adjacent vascular invasion and the presence of distant metastases. Neoadjuvant chemotherapy with gemcitabine and S-1 (NAC-GS) has recently become a standard option for resectable pancreatic cancer in Japanese patients. According to previous reports, GS is considered to be relatively safe and feasible treatment for Japanese patients, including the elderly. However, NAC-GS is occasionally associated with severe adverse events which may ultimately render the patient unfit for surgery. A 60-year-old man with resectable pancreatic cancer suffered from severe necrotic enteritis during NAC-GS, which required surgical resection. Considering the time course and histological findings of the resected bowel, S-1 was believed to be the causative agent. The low urinary dihydrouracil to uracil ratio also suggested possible dihydropyrimidine dehydrogenase deficiency, which may have hindered the metabolism of S-1 and contributed to the development of necrotic enteritis. Life-threatening enteritis occurs in approximately 0.3% of all patients who receive S-1. As initial symptoms are non-specific, patients should be instructed to lower the hurdle for contacting the hospital during NAC-GS.
AuthorsTakaaki Furukawa, Takashi Sasaki, Yoshihiro Ono, Fumihiro Kawano, Manabu Takamatsu, Chinatsu Mori, Takafumi Mie, Yuto Yamada, Takeshi Okamoto, Tsuyoshi Takeda, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Yu Takahashi, Naoki Sasahira
JournalClinical journal of gastroenterology (Clin J Gastroenterol) Vol. 14 Issue 5 Pg. 1571-1577 (Oct 2021) ISSN: 1865-7265 [Electronic] Japan
PMID34255287 (Publication Type: Case Reports, Journal Article)
Copyright© 2021. Japanese Society of Gastroenterology.
Chemical References
  • Deoxycytidine
  • Gemcitabine
Topics
  • Adenocarcinoma (drug therapy, surgery)
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Deoxycytidine (analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms (drug therapy)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: